Vibozilimod

Vibozilimod (SCD-044, Example 33) is an orally active and selective S1PR1/EDG1 agonist with an EC50 of less than 1 nM. Vibozilimod has immunomodulatory activity and can reduce the number of lymphocytes. Vibozilimod can be used in the research of inflammatory diseases such as psoriasis and atopic dermatitis[1][2].

Product Specifications

CAS Number

[1403232-33-6]

Product Name Alternative

SCD-044

UNSPSC

12352005

Target

LPL Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/vibozilimod.html

Purity

99.52

Solubility

Ethanol : 1.92 mg/mL (ultrasonic; warming; adjust pH to 5 with HCl; heat to 60°C)

Smiles

O=C(C1(COCCOC)CCN(CC2=CC=C(C3=NOC(C4=CC=C(CC(C)C)C(Cl)=C4)=N3)C=C2)CC1)O

Molecular Formula

C29H36ClN3O5

Molecular Weight

542.07

References & Citations

[1]Marc Capet, et al. Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists. Patent. WO2012140020A1. 2012-10-18.|[2]Drakos A, et al. A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians. Dermatol Ther (Heidelb) . 2022 Dec;12 (12) :2715-2730.